Cargando…

Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference

Incretin-based therapies have been gaining much attention recently as a new class of therapeutics for type 2 diabetes worldwide. Among them, glucagon-like peptide-1 receptor agonist liraglutide has been rapidly increasing its global usage. Once daily injection of liraglutide significantly ameliorate...

Descripción completa

Detalles Bibliográficos
Autores principales: Yabe, Daisuke, Seino, Yutaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411533/
https://www.ncbi.nlm.nih.gov/pubmed/22879794
http://dx.doi.org/10.4137/CMED.S5976
_version_ 1782239843866116096
author Yabe, Daisuke
Seino, Yutaka
author_facet Yabe, Daisuke
Seino, Yutaka
author_sort Yabe, Daisuke
collection PubMed
description Incretin-based therapies have been gaining much attention recently as a new class of therapeutics for type 2 diabetes worldwide. Among them, glucagon-like peptide-1 receptor agonist liraglutide has been rapidly increasing its global usage. Once daily injection of liraglutide significantly ameliorates glycemic control in patients with type 2 diabetes by enhancing insulin secretion and suppressing glucagon secretion glucose-dependently. Liraglutide delays gastric emptying and suppresses food intakes, both of which contribute to glucose lowering and weight reduction. Efficacy and safety of liraglutide in management of type 2 diabetes have been well documented in several key clinical trials such as series of phase 3 Liraglutide Effect and Action in Diabetes (LEAD) trials, and the liraglutide-versus-sitagliptin trial. Recent two trials dealing with monotherapy and sulfonylurea combination therapy on Japanese patients with type 2 diabetes furthermore indicate liraglutide’s effectiveness in non-obese diabetes. In this review, we summarize results from such clinical trials, and discuss efficacy and safety of liraglutide in management of type 2 diabetes in various countries, along with a pitfall of liraglutide usage in real clinical setting.
format Online
Article
Text
id pubmed-3411533
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-34115332012-08-09 Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference Yabe, Daisuke Seino, Yutaka Clin Med Insights Endocrinol Diabetes Review Incretin-based therapies have been gaining much attention recently as a new class of therapeutics for type 2 diabetes worldwide. Among them, glucagon-like peptide-1 receptor agonist liraglutide has been rapidly increasing its global usage. Once daily injection of liraglutide significantly ameliorates glycemic control in patients with type 2 diabetes by enhancing insulin secretion and suppressing glucagon secretion glucose-dependently. Liraglutide delays gastric emptying and suppresses food intakes, both of which contribute to glucose lowering and weight reduction. Efficacy and safety of liraglutide in management of type 2 diabetes have been well documented in several key clinical trials such as series of phase 3 Liraglutide Effect and Action in Diabetes (LEAD) trials, and the liraglutide-versus-sitagliptin trial. Recent two trials dealing with monotherapy and sulfonylurea combination therapy on Japanese patients with type 2 diabetes furthermore indicate liraglutide’s effectiveness in non-obese diabetes. In this review, we summarize results from such clinical trials, and discuss efficacy and safety of liraglutide in management of type 2 diabetes in various countries, along with a pitfall of liraglutide usage in real clinical setting. Libertas Academica 2011-09-13 /pmc/articles/PMC3411533/ /pubmed/22879794 http://dx.doi.org/10.4137/CMED.S5976 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Review
Yabe, Daisuke
Seino, Yutaka
Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
title Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
title_full Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
title_fullStr Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
title_full_unstemmed Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
title_short Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
title_sort liraglutide in adults with type 2 diabetes: global perspective on safety, efficacy and patient preference
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411533/
https://www.ncbi.nlm.nih.gov/pubmed/22879794
http://dx.doi.org/10.4137/CMED.S5976
work_keys_str_mv AT yabedaisuke liraglutideinadultswithtype2diabetesglobalperspectiveonsafetyefficacyandpatientpreference
AT seinoyutaka liraglutideinadultswithtype2diabetesglobalperspectiveonsafetyefficacyandpatientpreference